Direct healthcare cost of schizophrenia – European overview

G. Kovács, T. Almási, A. Millier, M. Toumi, M. Horváth, Kristóf Kóczián, Götze, Z. Kaló, A. T. Zemplényi

Research output: Contribution to journalShort survey

4 Citations (Scopus)

Abstract

Purpose: To provide an overview on the magnitude of the impact of schizophrenia on the healthcare system in Europe and to gain a better understanding on the most important factors influencing the variation of costs. Methods: Studies reporting costs and healthcare utilization among patients with schizophrenia were searched in MEDLINE (via Scopus), EMBASE (via Scopus) and Cochrane Database of Systematic Reviews on 19th January 2017. Results: Twenty-three studies, from the 1075 references initially identified, were included in this review. The annual cost per patient ranged from €533 in Ukraine to €13,704 in the Netherlands. Notably drug costs contributed to less than 25% of the direct healthcare cost per patient in every country, which might be explained by similar pharmaceutical prices among countries due to the reference pricing system applied in Europe. Inpatient costs were the largest component of health service costs in the majority of the countries. Despite methodological heterogeneity across studies, four major themes could be identified (age, severity of symptoms, continuation of treatment/persistence, hospitalization) that have substantial impact on the costs of schizophrenia. Conclusions: Schizophrenia represents a substantial cost for the healthcare system in Europe driven by the high cost per patient. Substantial savings could potentially be achieved by increasing investment in the following areas: (1) reducing the number of hospitalizations e.g. by increasing the efficiency of outpatient care; (2) working out interventions targeted at specific symptoms; (3) improving patient persistence and adherence in antipsychotic therapy.

Original languageEnglish
Pages (from-to)79-92
Number of pages14
JournalEuropean Psychiatry
Volume48
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Health Care Costs
Schizophrenia
Costs and Cost Analysis
Hospitalization
Delivery of Health Care
Ukraine
Drug Costs
Patient Compliance
Ambulatory Care
MEDLINE
Netherlands
Antipsychotic Agents
Health Services
Inpatients
Databases
Therapeutics
Pharmaceutical Preparations

Keywords

  • Cost of illness
  • Europe
  • Healthcare costs
  • Schizophrenia
  • Systematic review

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Kovács, G., Almási, T., Millier, A., Toumi, M., Horváth, M., Kóczián, K., ... Zemplényi, A. T. (2018). Direct healthcare cost of schizophrenia – European overview. European Psychiatry, 48, 79-92. https://doi.org/10.1016/j.eurpsy.2017.10.008

Direct healthcare cost of schizophrenia – European overview. / Kovács, G.; Almási, T.; Millier, A.; Toumi, M.; Horváth, M.; Kóczián, Kristóf; Götze, ; Kaló, Z.; Zemplényi, A. T.

In: European Psychiatry, Vol. 48, 01.02.2018, p. 79-92.

Research output: Contribution to journalShort survey

Kovács, G, Almási, T, Millier, A, Toumi, M, Horváth, M, Kóczián, K, Götze, , Kaló, Z & Zemplényi, AT 2018, 'Direct healthcare cost of schizophrenia – European overview', European Psychiatry, vol. 48, pp. 79-92. https://doi.org/10.1016/j.eurpsy.2017.10.008
Kovács G, Almási T, Millier A, Toumi M, Horváth M, Kóczián K et al. Direct healthcare cost of schizophrenia – European overview. European Psychiatry. 2018 Feb 1;48:79-92. https://doi.org/10.1016/j.eurpsy.2017.10.008
Kovács, G. ; Almási, T. ; Millier, A. ; Toumi, M. ; Horváth, M. ; Kóczián, Kristóf ; Götze, ; Kaló, Z. ; Zemplényi, A. T. / Direct healthcare cost of schizophrenia – European overview. In: European Psychiatry. 2018 ; Vol. 48. pp. 79-92.
@article{f98cfeb1a983458a93646f926d7c6439,
title = "Direct healthcare cost of schizophrenia – European overview",
abstract = "Purpose: To provide an overview on the magnitude of the impact of schizophrenia on the healthcare system in Europe and to gain a better understanding on the most important factors influencing the variation of costs. Methods: Studies reporting costs and healthcare utilization among patients with schizophrenia were searched in MEDLINE (via Scopus), EMBASE (via Scopus) and Cochrane Database of Systematic Reviews on 19th January 2017. Results: Twenty-three studies, from the 1075 references initially identified, were included in this review. The annual cost per patient ranged from €533 in Ukraine to €13,704 in the Netherlands. Notably drug costs contributed to less than 25{\%} of the direct healthcare cost per patient in every country, which might be explained by similar pharmaceutical prices among countries due to the reference pricing system applied in Europe. Inpatient costs were the largest component of health service costs in the majority of the countries. Despite methodological heterogeneity across studies, four major themes could be identified (age, severity of symptoms, continuation of treatment/persistence, hospitalization) that have substantial impact on the costs of schizophrenia. Conclusions: Schizophrenia represents a substantial cost for the healthcare system in Europe driven by the high cost per patient. Substantial savings could potentially be achieved by increasing investment in the following areas: (1) reducing the number of hospitalizations e.g. by increasing the efficiency of outpatient care; (2) working out interventions targeted at specific symptoms; (3) improving patient persistence and adherence in antipsychotic therapy.",
keywords = "Cost of illness, Europe, Healthcare costs, Schizophrenia, Systematic review",
author = "G. Kov{\'a}cs and T. Alm{\'a}si and A. Millier and M. Toumi and M. Horv{\'a}th and Krist{\'o}f K{\'o}czi{\'a}n and G{\"o}tze and Z. Kal{\'o} and Zempl{\'e}nyi, {A. T.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.eurpsy.2017.10.008",
language = "English",
volume = "48",
pages = "79--92",
journal = "Psychiatrie et Psychobiologie",
issn = "0924-9338",
publisher = "Psychiatrie & psychobiologie",

}

TY - JOUR

T1 - Direct healthcare cost of schizophrenia – European overview

AU - Kovács, G.

AU - Almási, T.

AU - Millier, A.

AU - Toumi, M.

AU - Horváth, M.

AU - Kóczián, Kristóf

AU - Götze,

AU - Kaló, Z.

AU - Zemplényi, A. T.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Purpose: To provide an overview on the magnitude of the impact of schizophrenia on the healthcare system in Europe and to gain a better understanding on the most important factors influencing the variation of costs. Methods: Studies reporting costs and healthcare utilization among patients with schizophrenia were searched in MEDLINE (via Scopus), EMBASE (via Scopus) and Cochrane Database of Systematic Reviews on 19th January 2017. Results: Twenty-three studies, from the 1075 references initially identified, were included in this review. The annual cost per patient ranged from €533 in Ukraine to €13,704 in the Netherlands. Notably drug costs contributed to less than 25% of the direct healthcare cost per patient in every country, which might be explained by similar pharmaceutical prices among countries due to the reference pricing system applied in Europe. Inpatient costs were the largest component of health service costs in the majority of the countries. Despite methodological heterogeneity across studies, four major themes could be identified (age, severity of symptoms, continuation of treatment/persistence, hospitalization) that have substantial impact on the costs of schizophrenia. Conclusions: Schizophrenia represents a substantial cost for the healthcare system in Europe driven by the high cost per patient. Substantial savings could potentially be achieved by increasing investment in the following areas: (1) reducing the number of hospitalizations e.g. by increasing the efficiency of outpatient care; (2) working out interventions targeted at specific symptoms; (3) improving patient persistence and adherence in antipsychotic therapy.

AB - Purpose: To provide an overview on the magnitude of the impact of schizophrenia on the healthcare system in Europe and to gain a better understanding on the most important factors influencing the variation of costs. Methods: Studies reporting costs and healthcare utilization among patients with schizophrenia were searched in MEDLINE (via Scopus), EMBASE (via Scopus) and Cochrane Database of Systematic Reviews on 19th January 2017. Results: Twenty-three studies, from the 1075 references initially identified, were included in this review. The annual cost per patient ranged from €533 in Ukraine to €13,704 in the Netherlands. Notably drug costs contributed to less than 25% of the direct healthcare cost per patient in every country, which might be explained by similar pharmaceutical prices among countries due to the reference pricing system applied in Europe. Inpatient costs were the largest component of health service costs in the majority of the countries. Despite methodological heterogeneity across studies, four major themes could be identified (age, severity of symptoms, continuation of treatment/persistence, hospitalization) that have substantial impact on the costs of schizophrenia. Conclusions: Schizophrenia represents a substantial cost for the healthcare system in Europe driven by the high cost per patient. Substantial savings could potentially be achieved by increasing investment in the following areas: (1) reducing the number of hospitalizations e.g. by increasing the efficiency of outpatient care; (2) working out interventions targeted at specific symptoms; (3) improving patient persistence and adherence in antipsychotic therapy.

KW - Cost of illness

KW - Europe

KW - Healthcare costs

KW - Schizophrenia

KW - Systematic review

UR - http://www.scopus.com/inward/record.url?scp=85041606685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041606685&partnerID=8YFLogxK

U2 - 10.1016/j.eurpsy.2017.10.008

DO - 10.1016/j.eurpsy.2017.10.008

M3 - Short survey

C2 - 29428166

AN - SCOPUS:85041606685

VL - 48

SP - 79

EP - 92

JO - Psychiatrie et Psychobiologie

JF - Psychiatrie et Psychobiologie

SN - 0924-9338

ER -